Sunifiram (also known as DM-235) is a small experimental molecule being studied in relation to cognitive function, synaptic plasticity, and modulation of glutamatergic pathways (particularly AMPA).
Contents
Unspecified (oral capsule form)
Concentration (test)
Unspecified
Packaging
Sealable packaging (capsules)
Storage
Store in a dry place, at room temperature, away from light.
Molecular formula
Unspecified
Molecular weight
Unspecified
Other names
Sunifiram, DM-235
In laboratory studies, Sunifiram has been linked to research in areas such as:
- memory, learning and long-term potentiation (LTP),
- modulation of AMPA/NMDA signaling and synaptic plasticity,
- attention, alertness and psychomotor functions,
- cholinergic neurotransmission and acetylcholine balance,
- resistance to cognitive fatigue in experimental models.
This content is for educational purposes only. It is not a recommendation for human use. The substance is intended for laboratory research only.
What is Sunifiram?
Sunifiram (DM-235) is a small, lipophilic experimental compound that the literature classifies as an “ampakine” modulator targeting glutamatergic receptors. In model systems, it has been associated with effects on memory storage, attention, and synaptic plasticity.
From a research perspective, the subject of interest is its effect on cognitive processes, exclusively under experimental conditions.
How Sunifiram works
Experiments have reported positive modulation of glutamatergic pathways (particularly AMPA receptors) and mediated changes in NMDA signaling. This effect may promote synaptic plasticity and long-term potentiation (LTP) mechanisms that are core to learning and memory in model conditions.
Additionally, interaction with the cholinergic system and changes in acetylcholine availability are being monitored, which may contribute to the perception of wakefulness and attention.
Researched effects and interesting facts
-
Memory and learning: Indications for promoting LTP and memory trace consolidation.
-
Attention: Parameters of alertness and reaction times are monitored.
-
Synaptic plasticity: Impact on AMPA/NMDA signaling in models.
-
Cholinergic modulation: Possible changes in cholinergic neurotransmission.
-
Cognitive fatigue: Potential effect on subjective fatigue in experimental protocols.
Dosage in studies
The values listed are derived solely from research studies and are not intended for real-world use outside of a laboratory environment.
-
Dose: 5–20 mg daily (model oral protocols)
-
Form: oral (capsules)
-
Frequency: 1x daily according to study objective
-
Duration: 4 – 8 weeks within experimental protocols
The dosage information is provided as a summary of data from experimental sources only. It does not constitute instructions for use or a recommendation.
Possible side effects
- Insomnia, nervousness or headaches (especially with late administration in models)
- Nausea or dyspeptic symptoms
- Rare vegetative manifestations (changes in blood pressure, heart rate) depending on the protocol
Resources
- Experimental work on the modulation of AMPA/NMDA receptors by small molecules
- Studies of synaptic plasticity and long-term potentiation (LTP) in model systems
- Review publications on cholinergic neurotransmission and cognitive functions
- Methodological protocols for oral dosage models in capsule form
This article is for informational purposes only. It does not constitute a recommendation or solicitation for use. The information provided is a summary of existing scientific literature and is for educational purposes only.
Sale
